Jointly provided by
This activity is supported by independent educational grants from Baxter BioScience, Bayer HealthCare Pharmaceuticals Inc., Biogen Idec, CSL Behring, and Novo Nordisk, Inc.
Hemophilia Pharmacy Management: Steps for Success With Managed Care and Specialty Pharmacy — Case Study Compendium: A Focus on Commercial, Medicaid, and Medicare Coverage
DISTINGUISHED FACULTY | ||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
TARGET AUDIENCE
STATEMENT OF NEED/PROGRAM OVERVIEW
Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes require a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans, and employers in meeting clinical and/or financial goals. This enduring activity will emphasize the need for well-coordinated treatment management, the importance of understanding effective ways of using available treatments, and the importance of collaboration among all stakeholders.
ACCREDITATION
Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, National Hemophilia Foundation, and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation (all 3 cases)
Postgraduate Institute for Medicine designates these enduring materials for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Credit Designation (all 3 cases)
Postgraduate Institute for Medicine designates these continuing education activities for 1.2 contact hours (0.12 CEUs) of the Accreditation Council for Pharmacy Education.
Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
Nursing Continuing Education
Credit Designation (all 3 cases)
These educational activities for up to 1.2 contact hours are provided by Postgraduate Institute for Medicine.
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Faculty or Presenter | Reported Financial Relationship |
Jeffrey D. Dunn, PharmD, MBA | Consulting Fees: Baxter BioScience, Biogen Idec, Genzyme Corporation, Teva Pharmaceutical Industries |
John Grossomanides, PharmD, RPh | No financial interest/relationships relating to the topic of this activity |
John W. Knispel, MD, CPE, FACOG | No financial interest/relationships relating to the topic of this activity |
Jennifer Maahs, RN, PNP, MSN | Consulting Fees: Baxter BioScience, Biogen Idec, Novo Nordisk, Inc. |
Steven W. Pipe, MD | Consulting Fees: Baxter BioScience, Bayer HealthCare Pharmaceuticals, CSL Behring, Novo Nordisk, Inc., Pfizer, Inc. Grant Funding: Baxter, Pfizer, Inc. |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Planner or Manager | Reported Financial Relationship |
Steven Casebeer, MBA | No financial interest/relationships relating to the topic of this activity |
Michelle Rice | No financial interest/relationships relating to the topic of this activity |
Marla Feinstein | No financial interest/relationships relating to the topic of this activity |
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCPhereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 15, 2015 through December 31, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.
For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
MEDIA
Internet
FEE INFORMATION
There is no fee for this educational activity.